2020 Year in Review : Pharmacologic Treatments for COVID-19
Copyright © 2021 by Daedalus Enterprises..
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 infection, has led to a pandemic of acute respiratory illness. Pharmacologic treatments for COVID-19 have included treatments that target infection prevention, prevention of viral replication, reduce inflammation, and manage symptoms of respiratory failure caused by the disease. This is a review of key pharmacologic treatments for COVID-19 based on peer-reviewed articles from 2020.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Respiratory care - 66(2021), 7 vom: 14. Juli, Seite 1167-1172 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Saunders, Jessica L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Airway pH |
|---|
| Anmerkungen: |
Date Completed 08.07.2021 Date Revised 30.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4187/respcare.09153 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324012918 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324012918 | ||
| 003 | DE-627 | ||
| 005 | 20231225185418.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4187/respcare.09153 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM324012918 | ||
| 035 | |a (NLM)33846276 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Saunders, Jessica L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 2020 Year in Review |b Pharmacologic Treatments for COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.07.2021 | ||
| 500 | |a Date Revised 30.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 by Daedalus Enterprises. | ||
| 520 | |a Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 infection, has led to a pandemic of acute respiratory illness. Pharmacologic treatments for COVID-19 have included treatments that target infection prevention, prevention of viral replication, reduce inflammation, and manage symptoms of respiratory failure caused by the disease. This is a review of key pharmacologic treatments for COVID-19 based on peer-reviewed articles from 2020 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Optate | |
| 650 | 4 | |a REGN-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a airway pH | |
| 650 | 4 | |a dexamethasone | |
| 650 | 4 | |a remdesivir | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Davis, Michael D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory care |d 1974 |g 66(2021), 7 vom: 14. Juli, Seite 1167-1172 |w (DE-627)NLM07486520X |x 1943-3654 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2021 |g number:7 |g day:14 |g month:07 |g pages:1167-1172 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4187/respcare.09153 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2021 |e 7 |b 14 |c 07 |h 1167-1172 | ||